seladelpar
EMA Supports Approval of Gilead’s Liver Disease Drug from $4.3B CymaBay Acquisition
Gilead Sciences, CymaBay Therapeutics, seladelpar, primary biliary cholangitis (PBC), liver disease, EMA approval, $4.3 billion deal
Gilead Sciences Exceeds Q2 Expectations, Boosts Optimism for Seladelpar Decision
Gilead Sciences, Q2 earnings, seladelpar, PBC, liver disease, financial performance, pharmaceuticals